Vivos Therapeutics (VVOS) Stock Overview
Operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
VVOS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vivos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.19 |
| 52 Week High | US$7.95 |
| 52 Week Low | US$1.98 |
| Beta | 6.87 |
| 1 Month Change | -22.57% |
| 3 Month Change | -38.30% |
| 1 Year Change | 27.09% |
| 3 Year Change | -82.06% |
| 5 Year Change | n/a |
| Change since IPO | -98.58% |
Recent News & Updates
Recent updates
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected
Jul 02
FDA Clearance And Middle East Expansion Will Secure Future Success
Strategic alliances and clinic acquisitions aim to increase patient conversions, boosting revenue and margins through higher treatment uptake.Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump
Apr 05Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding
Feb 16After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar
Dec 27Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely
Nov 12Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Sep 10It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Shareholder Returns
| VVOS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.2% | 3.7% | 1.2% |
| 1Y | 27.1% | -19.5% | 17.7% |
Return vs Industry: VVOS exceeded the US Healthcare industry which returned -19.3% over the past year.
Return vs Market: VVOS exceeded the US Market which returned 17.9% over the past year.
Price Volatility
| VVOS volatility | |
|---|---|
| VVOS Average Weekly Movement | 14.2% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VVOS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VVOS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 113 | R. Huntsman | www.vivos.com |
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
Vivos Therapeutics, Inc. Fundamentals Summary
| VVOS fundamental statistics | |
|---|---|
| Market cap | US$23.94m |
| Earnings (TTM) | -US$14.32m |
| Revenue (TTM) | US$14.39m |
Is VVOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVOS income statement (TTM) | |
|---|---|
| Revenue | US$14.39m |
| Cost of Revenue | US$6.35m |
| Gross Profit | US$8.05m |
| Other Expenses | US$22.37m |
| Earnings | -US$14.32m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 55.91% |
| Net Profit Margin | -99.50% |
| Debt/Equity Ratio | 172.7% |
How did VVOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 03:07 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivos Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Lucas Ward | Ascendiant Capital Markets LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |